Treatment of malignant glioma using hyperthermia

Jiahang Sun, Mian Guo, Hengyuan Pang, Jingtao Qi, Jinwei Zhang, Yunlong Ge, Jiahang Sun, Mian Guo, Hengyuan Pang, Jingtao Qi, Jinwei Zhang, Yunlong Ge

Abstract

Thirty pathologically diagnosed patients with grade III-IV primary or recurrent malignant glioma (tumor diameter 3-7 cm) were randomly divided into two groups. The control group underwent conventional radiotherapy and chemotherapy. In the hyperthermia group, primary cases received hyperthermia treatment, and patients with recurrent tumors were treated with hyperthermia in com-bination with radiotherapy and chemotherapy. Hyperthermia treatment was administered using a 13.56-MHz radio frequency hyperthermia device. Electrodes were inserted into the tumor with the aid of a CT-guided stereotactic apparatus and heat was applied for 1 hour. During 3 months after hyperthermia, patients were evaluated with head CT or MRI every month. Gliomas in the hyper-thermia group exhibited growth retardation or growth termination. Necrosis was evident in 80% of the heated tumor tissue and there was a decrease in tumor diameter. Our findings indicate that ra-dio frequency hyperthermia has a beneficial effect in the treatment of malignant glioma.

Keywords: CT; MRI; clinical effects; glioma; grants-supported paper; intracranial hypertension; malignant tumor; necrosis; neural regeneration; neuroregeneration; radio frequency hyperthermia; recurrence.

Conflict of interest statement

Conflicts of interest: None declared.

Figures

Figure 1
Figure 1
A 24-year-old man with grade III recurrent glioma. (A, B) Brain tumor showing an irregular enhancing signal shadow (arrows) on CT before treatment. (C, D) CT scan showing internal liquefaction and tumor necrosis (arrows) in low-density images at 7 days after hyperthermia (hyperthermia + radiotherapy + chemotherapy). (E, F) MRI scan showing increased tumor necrosis (arrows) and surrounding tissue with no obvious enhancement at 12 months after hyperthermia.
Figure 2
Figure 2
A 28-year-old man with grade III recurrent astrocytoma. (A, B) A tumor located in the contralateral frontal with an irregular mass shadow and unclear boundaries (arrows) on CT before treatment. (C, D) A CT scan at 3 months after hyperthermia (hyperthermia + radiotherapy + chemotherapy), showing that stereotactic radiosurgery had targeted the tumor (arrows). (E, F) An MRI scan at 18 months after hyperthermia showing that the tumor signals and pressure on the brain ventricles had disappeared (arrows).

References

    1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
    1. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115(24):5761–5770.
    1. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–3068.
    1. Liang ML, Ma J, Ho M, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87(3):247–253.
    1. Guthkelch AN, Carter LP, Cassady JR, et al. Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial. J Neurooncol. 1991;10(3):271–284.
    1. Kakinuma K, Tanaka R, Takahashi H, et al. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J Neurosurg. 1996;84(2):180–184.
    1. Kakinuma K, Tanaka R, Takahashi H, et al. Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int J Hyperthermia. 1996;12(1):157–165.
    1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
    1. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103(2):143–153.
    1. Marchosky JA, Moran CJ, Fearnot NE, et al. Hyperthermia catheter implantation and therapy in the brain. Technical note. J Neurosurg. 1990;72(6):975–979.
    1. Moriyama E, Salcman M, Broadwell RD. Blood-brain barrier alteration after microwave-induced hyperthermia is purely a thermal effect: I. Temperature and power measurements. Surg Neurol. 1991;35(3):177–182.
    1. Roberts DW, Coughlin CT, Wong TZ, et al. Interstitial hyperthermia and iridium brachytherapy in treatment of malignant glioma. A phase I clinical trial. J Neurosurg. 1986;64(4):581–587.
    1. Ryan TP, Hoopes PJ, Taylor JH, et al. Experimental brain hyperthermia: techniques for heat delivery and thermometry. Int J Radiat Oncol Biol Phys. 1991;20(4):739–750.
    1. Dayanc BE, Beachy SH, Ostberg JR, et al. Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperthermia. 2008;24(1):41–56.
    1. Peake J, Peiffer JJ, Abbiss CR, et al. Body temperature and its effect on leukocyte mobilization, cytokines and markers of neutrophil activation during and after exercise. Eur J Appl Physiol. 2008;102(4):391–401.
    1. Roberts GT, Ghebeh H, Chishti MA, et al. Microvascular injury, thrombosis, inflammation, and apoptosis in the pathogenesis of heatstroke: a study in baboon model. Arterioscler Thromb Vasc Biol. 2008;28(6):1130–1136.
    1. Nagarsekar A, Greenberg RS, Shah NG, et al. Febrile- range hyperthermia accelerates caspase-dependent apoptosis in human neutrophils. J Immunol. 2008;181(4):2636–2643.
    1. Huang TQ, Lee MS, Oh E, et al. Molecular responses of Jurkat T-cells to 1763 MHz radiofrequency radiation. Int J Radiat Biol. 2008;84(9):734–741.
    1. Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138(5):1931–1942.
    1. Tanaka R, Kim CH, Yamada N, et al. Radiofrequency hyperthermia for malignant brain tumors: preliminary results of clinical trials. Neurosurgery. 1987;21(4):478–483.
    1. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53–60.
    1. van Landeghem FK, Maier-Hauff K, Jordan A, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30(1):52–57.
    1. Bouchama A, Knochel JP. Heat stroke. N Engl J Med. 2002;346(25):1978–1988.
    1. Marchosky JA, Welsh DM, Moran CJ. Hyperthermia treatment of brain tumors. Mo Med. 1990;87(1):29–33.
    1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.
    1. Atanackovic D, Pollok K, Faltz C, et al. Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R585–594.
    1. Dayanc BE, Beachy SH, Ostberg JR, et al. Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperthermia. 2008;24(1):41–56.
    1. Meinander A, Söderström TS, Kaunisto A, et al. Fever-like hyperthermia controls T Lymphocyte persistence by inducing degradation of cellular FLIPshort. J Immunol. 2007;178(6):3944–3953.
    1. Sharma HS, Hoopes PJ. Hyperthermia induced pathophysiology of the central nervous system. Int J Hyperthermia. 2003;19(3):325–354.
    1. Sharma HS. Hyperthermia induced brain oedema: current status and future perspectives. Indian J Med Res. 2006;123(5):629–652.
    1. Hurwitz MD, Hansen JL, Prokopios-Davos S, et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer. 2011;117(3):510–516.
    1. Balivada S, Rachakatla RS, Wang H, et al. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer. 2010;10:119.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner